{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:06:55Z","timestamp":1789020415336,"version":"build-2803163510"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"publisher","award":["Creative-Pioneering Researchers Program"],"award-info":[{"award-number":["Creative-Pioneering Researchers Program"]}],"id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2023R1A2C1006820"],"award-info":[{"award-number":["NRF-2023R1A2C1006820"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Propranolol is a widely-used \u03b2-adrenergic blocker with extensive pharmacokinetic (PK) data across multiple species, rendering it appropriate for comparing various interspecies scaling methodologies. The present study aimed to apply a quantitative interspecies PK modeling framework for propranolol using literature-derived datasets from seven mammalian species, namely, mouse, rat, rabbit, cat, dog, human, and horse. Conventional allometric analyses indicated body weight-dependent relationships for both clearance and steady-state volume of distribution. For the top-down minimal physiologically-based pharmacokinetic (mPBPK) modeling approach, the model incorporated two peripheral tissue compartments governed by shared distribution parameters across different species. The simultaneous fitting of intravenous (IV) propranolol PK data from seven species to the mPBPK model produced parameter estimates that reasonably captured the observed plasma PK data. Subsequent individual fitting of IV and oral propranolol PK data for each species adequately estimated additional absorption-related parameters. To improve physiological interpretability, top-down parameter estimates were aligned with bottom-up whole-body PBPK parameters via tissue-lumping principles. A unitless product-ratio plot further provided species-dependent kinetic distinctions on the biological half-lives of propranolol. Finally, translational performance was evaluated by scaling preclinical datasets, where the mPBPK model derived from three common preclinical species provided reasonable predictions of human IV PK profiles. Collectively, these findings provide a clearer physiological interpretation of propranolol disposition across species. Building upon the previous efforts using mPBPK modeling, the current study demonstrates a more mechanistically informed, refined workflow for interspecies scaling and translational human PK prediction applicable to drug candidates.<\/jats:p>","DOI":"10.3389\/fphar.2026.1933766","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:31:00Z","timestamp":1789018260000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-species assessment of propranolol pharmacokinetics via minimal and whole-body PBPK modeling"],"prefix":"10.3389","volume":"17","author":[{"given":"Minsoo","family":"Lee","sequence":"first","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Ji","family":"Ji","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo-Seong","family":"Jeong","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooin","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/s0169-409x(01)00179-x","article-title":"Predicting the impact of physiological and biochemical processes on oral drug bioavailability","volume":"50","author":"Agoram","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejps.2017.05.012","article-title":"Glucosamine modulates propranolol pharmacokinetics via intestinal permeability in rats","volume":"105","author":"Al Shaker","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1365-2710.1993.tb00564.x","article-title":"Effect of oral activated charcoal on propranolol pharmacokinetics following intravenous administration to rabbits","volume":"18","author":"Al-Meshal","year":"1993","journal-title":"J. Clin. Pharm. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1248\/bpb.23.1333","article-title":"Pharmacokinetics of propranolol and its metabolites in horses after intravenous or oral administration","volume":"23","author":"Aramaki","year":"2000","journal-title":"Biol. Pharm. Bull."},{"key":"B5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1159\/000173684","article-title":"Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol","volume":"71","author":"Arendt","year":"1984","journal-title":"Cardiology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/j.1552-4604.1995.tb04076.x","article-title":"The effect of dosage release formulations on the pharmacokinetics of propranolol stereoisomers in humans","volume":"35","author":"Bleske","year":"1995","journal-title":"J. Clin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/BF01060886","article-title":"Pharmacokinetics of propranolol","volume":"9","author":"Borgstrom","year":"1981","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/BF01062336","article-title":"Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics","volume":"10","author":"Boxenbaum","year":"1982","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"B9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1365-2125.1976.tb00599.x","article-title":"A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol","volume":"3","author":"Branch","year":"1976","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/074823379701300401","article-title":"Physiological parameter values for physiologically based pharmacokinetic models","volume":"13","author":"Brown","year":"1997","journal-title":"Toxicol. Ind. Health"},{"key":"B11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-012-9280-2","article-title":"Applications of minimal physiologically-based pharmacokinetic models","volume":"39","author":"Cao","year":"2012","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1021\/ac0516178","article-title":"Supercritical fluid chromatography-tandem mass spectrometry for the enantioselective determination of propranolol and pindolol in mouse blood by serial sampling","volume":"78","author":"Chen","year":"2006","journal-title":"Anal. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40005-025-00770-6","article-title":"Meta-analysis of levamisole absorption and disposition across diverse species using a minimal physiologically-based pharmacokinetic model","volume":"56","author":"Cheng","year":"2026","journal-title":"J. Pharm. Investig."},{"key":"B14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bph.14071","article-title":"Whole body physiologically based modelling of beta-blockers in the rat: events in tissues and plasma following an i.v. bolus dose","volume":"175","author":"Cheung","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"B15","volume-title":"ADAPT 5 user\u2019s guide: pharmacokinetic\/pharmacodynamic systems analysis software","author":"D\u2019Argenio","year":"2009"},{"key":"B16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/10837450902891360","article-title":"Physiologically based pharmacokinetics (PBPK)","volume":"41","author":"Espie","year":"2009","journal-title":"Drug Metab. Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/BF01061479","article-title":"Theorems and implications of a model-independent elimination\/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics","volume":"13","author":"Gillespie","year":"1985","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"B18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/BF01065394","article-title":"Pharmacokinetics of propranolol in normal healthy volunteers","volume":"5","author":"Gomeni","year":"1977","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"B19","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2460\/ajvr.1997.58.04.398","article-title":"Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states","volume":"58","author":"Jacobs","year":"1997","journal-title":"Am. J. Vet. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/ph14060545","article-title":"Meta-assessment of metformin absorption and disposition pharmacokinetics in nine species","volume":"14","author":"Jeong","year":"2021","journal-title":"Pharmaceuticals"},{"key":"B21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11095-022-03211-3","article-title":"Consideration of fractional distribution parameter f(d) in the Chen and gross method for tissue-to-plasma partition coefficients: Comparison of several methods","volume":"39","author":"Jeong","year":"","journal-title":"Pharm. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1208\/s12248-022-00739-5","article-title":"Determinants of biological half-lives and terminal slopes in physiologically based pharmacokinetic systems: assessment of limiting conditions","volume":"24","author":"Jeong","year":"","journal-title":"AAPS J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1208\/s12248-022-00779-x","article-title":"Theoretical examination seeking tangible physical meanings of slopes and intercepts of plasma concentration-time relationships in minimal physiologically based pharmacokinetic models","volume":"25","author":"Jeong","year":"2023","journal-title":"AAPS J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.xphs.2023.05.019","article-title":"A complete extension of classical hepatic clearance models using fractional distribution parameter f(d) in physiologically based pharmacokinetics","volume":"113","author":"Jeong","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2017.01.026","article-title":"Estimation of the minimum permeability coefficient in rats for perfusion-limited tissue distribution in whole-body physiologically-based pharmacokinetics","volume":"115","author":"Jeong","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1208\/s12248-022-00732-y","article-title":"Determination of the number of tissue groups of kinetically distinct transit time in whole-body physiologically based pharmacokinetic (PBPK) models I: theoretical consideration of Bottom-Up approach of lumping tissues in whole-body PBPK","volume":"24","author":"Jeong","year":"","journal-title":"AAPS J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1208\/s12248-022-00733-x","article-title":"Determination of the number of tissue groups of kinetically distinct transit time in whole-body physiologically based pharmacokinetic (PBPK) models II: practical application of tissue lumping theories for pharmacokinetics of various compounds","volume":"24","author":"Jeong","year":"","journal-title":"AAPS J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/hep.1840050411","article-title":"A carrier-protein receptor is not a prerequisite for avid hepatic elimination of highly bound compounds: a study of propranolol elimination by the isolated perfused rat liver","volume":"5","author":"Jones","year":"1985","journal-title":"Hepatology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1208\/s12248-025-01191-x","article-title":"Metronidazole pharmacokinetics across species: meta-analysis integrating allometric scaling and minimal physiologically-based pharmacokinetic modeling","volume":"28","author":"Kir","year":"2025","journal-title":"AAPS J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1002\/jps.20490","article-title":"Application of substrate depletion assay for early prediction of nonlinear pharmacokinetics in drug discovery: assessment of nonlinearity of metoprolol, timolol, and propranolol","volume":"94","author":"Komura","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/chir.530060508","article-title":"Influence of endotoxin on the stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil in the rat","volume":"6","author":"Laethem","year":"1994","journal-title":"Chirality"},{"key":"B32","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/chir.530070811","article-title":"Stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil: species differences and influence of endotoxin","volume":"7","author":"Laethem","year":"1995","journal-title":"Chirality"},{"key":"B33","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1021\/js960440h","article-title":"Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs","volume":"86","author":"Lave","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1211\/0022357991776840","article-title":"Effects of cyclosporin on the pharmacokinetics of propranolol after intravenous and oral administration to control rats and to rats with uranyl nitrate-induced acute renal failure","volume":"51","author":"Lee","year":"1999","journal-title":"J. Pharm. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/00498250701704819","article-title":"Intestinal permeability and its relevance for absorption and elimination","volume":"37","author":"Lennernas","year":"2007","journal-title":"Xenobiotica"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1472-6904-2-5","article-title":"PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol","volume":"2","author":"Levitt","year":"2002","journal-title":"BMC Clin. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0014-2999(76)90358-7","article-title":"Disposition of propranolol isomers in mice","volume":"40","author":"Levy","year":"1976","journal-title":"Eur. J. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1177\/009127000004001214","article-title":"Interspecies scaling: role of protein binding in the prediction of clearance from animals to humans","volume":"40","author":"Mahmood","year":"2000","journal-title":"J. Clin. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.tips.2015.07.006","article-title":"Fitting transporter activities to cellular drug concentrations and fluxes: why the bumblebee can fly","volume":"36","author":"Mendes","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/clpt.1984.107","article-title":"Stereoselective clearance and distribution of intravenous propranolol","volume":"35","author":"Olanoff","year":"1984","journal-title":"Clin. Pharmacol. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/jps.10128","article-title":"Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition","volume":"91","author":"Poulin","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/jps.20323","article-title":"Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat","volume":"94","author":"Rodgers","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF01059626","article-title":"Clearance concepts in pharmacokinetics","volume":"1","author":"Rowland","year":"1973","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e70293","DOI":"10.1002\/psp4.70293","article-title":"Butorphanol pharmacokinetics across species: meta-analysis integrating allometric scaling and minimal physiologically based pharmacokinetic modeling","volume":"15","author":"Saeed","year":"2026","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1248\/bpb1978.12.549","article-title":"The inhibitory effects of cimetidine on elimination and distribution of propranolol in rats","volume":"12","author":"Shibasaki","year":"1989","journal-title":"J. Pharmacobiodyn."},{"key":"B46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/bdd.2266","article-title":"Across-species meta-analysis of dexamethasone pharmacokinetics utilizing allometric and scaling modeling approaches","volume":"42","author":"Song","year":"2021","journal-title":"Biopharm. Drug Dispos."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e97885","DOI":"10.1371\/journal.pone.0097885","article-title":"A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls","volume":"9","author":"Taegtmeyer","year":"2014","journal-title":"PLoS One"},{"key":"B48","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1365-2125.1981.tb01263.x","article-title":"The distribution of propranolol, pindolol and atenolol between human erythrocytes and plasma","volume":"12","author":"Taylor","year":"1981","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/BF01059557","article-title":"Theorems and implications of a model independent elimination\/distribution function decomposition of linear and some nonlinear drug dispositions. I. Derivations and theoretical analysis","volume":"12","author":"Veng-Pedersen","year":"1984","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"B50","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/BF00877826","article-title":"Influences of the calcium antagonists nicardipine and nifedipine, and the calcium agonist BAY-K-8644, on the pharmacokinetics of propranolol in rats","volume":"7","author":"Vercruysse","year":"1993","journal-title":"Cardiovasc Drugs Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/chir.530040202","article-title":"The influence of aging on the stereoselective pharmacokinetics of propranolol in the rat","volume":"4","author":"Vermeulen","year":"1992","journal-title":"Chirality"},{"key":"B52","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/chir.530010303","article-title":"Stereochemistry of tissue distribution of racemic propranolol in the dog","volume":"1","author":"Walle","year":"1989","journal-title":"Chirality"},{"key":"B53","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1124\/dmd.32.6.603","article-title":"A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance","volume":"32","author":"Ward","year":"","journal-title":"Drug Metab. Dispos."},{"key":"B54","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1124\/dmd.32.6.612","article-title":"A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time","volume":"32","author":"Ward","year":"","journal-title":"Drug Metab. Dispos."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/s0024-3205(98)00053-8","article-title":"Species differences in the disposition of propranolol prodrugs derived from hydrolase activity in intestinal mucosa","volume":"62","author":"Yoshigae","year":"1998","journal-title":"Life Sci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s0378-5173(99)00147-7","article-title":"A compartmental absorption and transit model for estimating oral drug absorption","volume":"186","author":"Yu","year":"1999","journal-title":"Int. J. Pharm."},{"key":"B57","doi-asserted-by":"publisher","first-page":"103719","DOI":"10.1016\/j.xphs.2025.103719","article-title":"Physiologically-based modeling of methylprednisolone pharmacokinetics across species with extrapolations to humans","volume":"114","author":"Yu","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/bdd.70017","article-title":"Across-species meta-analysis of betamethasone pharmacokinetics utilizing a minimal PBPK model","volume":"46","author":"Zhang","year":"2025","journal-title":"Biopharm. Drug Dispos."},{"key":"B59","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s11095-015-1703-5","article-title":"Across-species scaling of monoclonal antibody pharmacokinetics using a minimal PBPK model","volume":"32","author":"Zhao","year":"2015","journal-title":"Pharm. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1933766\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:31:01Z","timestamp":1789018261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1933766\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":59,"alternative-id":["10.3389\/fphar.2026.1933766"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1933766","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"1933766"}}